• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Sonelokimab 120 mg or less showed significant clinical benefit over placebo in patients with plaque psoriasis

byNeel MistryandTeddy Guo
May 5, 2021
in Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. At 12 weeks, the proportion of patients with an IGA score of 0 or 1 was significantly greater in the sonelokimab groups than in the placebo group.

2. No dose-response associations with toxicity were apparent for the sonelokimab groups.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Sonelokimab is a novel trivalent nanobody comprised of monovalent moieties specific to human interleukin (IL)-17A, IL-17F, and human serum albumin. Studies assessing the inhibition of binding of IL-17A to IL-17RA have shown increased efficacy with sonelokimab, allowing it to be used as a potential treatment for plaque-type psoriasis. This randomized controlled trial aimed to assess the safety, efficacy, and tolerability of sonelokimab versus placebo in patients with plaque-type psoriasis, with secukinumab serving as an active control. The primary outcome was the proportion of patients receiving sonelokimab with an Investigator’s Global Assessment (IGA) score of 0 or 1 at week 12, while secondary outcomes included Psoriasis Area & Severity Index (PASI) responses, change in body surface area of psoriasis, and safety evaluations. According to study results, sonelokimab 120 mg or less showed significant clinical benefit over placebo, with respect to time-to-onset of treatment, durable improvements, and acceptable safety profile. A limitation of this study is that it did not assess the effect of either treatment on systemic diseases of plaque psoriasis such as metabolic syndrome and cardiovascular disease. Nevertheless, this study expands our understanding of the use of trivalent nanobodies for the treatment of plaque psoriasis.

Click to read the study in The Lancet

Relevant Reading: Bimekizumab versus Secukinumab in Plaque Psoriasis

In-depth [randomized controlled trial]: Between Aug 15, 2018, and Mar 27, 2019, 383 patients were assessed across 41 clinics in seven countries. Included patients were those aged 18-75 years with stable moderate to severe plaque-type psoriasis (defined as IGA ≥ 3, body surface area involvement ≥ 10%, and PASI ≥ 12) for ≥ 6 months before randomization. Those previously treated with ≥ 2 biologics or therapy targeting IL-17 were excluded. Altogether, 313 patients (52 in the placebo, sonelokimab 30 mg and 60 mg groups, 53 in the sonelokimab 120 mg normal load and secukinumab 300 mg groups, and 51 in the sonelokimab 120 mg augmented load group) were included in the analysis. Baseline characteristics were similar across groups.

RELATED REPORTS

Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa

Risk of hydroxychloroquine retinopathy increases with longer use and higher dosage

Bimekizumab is effective for active psoriatic arthritis in biologic-naĂŻve adults

At week 12, 0.0% (95% confidence interval [CI] 0.0-6.8, p<0.0001) patients in the placebo group had an IGA score of 0 or 1 compared to 48.1% (95% CI 34.0-62.4, p<0.0001) in the sonelokimab 30 mg group, 84.6% (95% CI 71.9-93.1, p<0.0001) in the sonelokimab 60 mg group, 77.4% (95% CI 63.8-87.7, p<0.0001) in the sonelokimab 120 mg normal load group, 88.2% (95% CI 76.1-95.6, p<0.0001) in the sonelokimab 120 mg augmented load group, and 77.4% (95% CI 63.8-87.7, p<0.0001) in the secukinumab 300 mg group. During the induction period, 49.5% (155 of 313) patients had one or more mild to moderate adverse events; the most frequent being nasopharyngitis (13.5%), pruritis (6.7%), and upper respiratory tract infection (4.3%) in all patients on sonelokimab during weeks 0-12. Over the 52-week study period, sonelokimab safety was similar to secukinumab, with the only exception being manageable Candida infections (1.9% in the secukinumab group vs. 17.4% in all sonelokimab-containing groups). Findings from this study suggest that sonelokimab may be superior to placebo for treatment of plaque-related psoriasis.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: autoimmune diseaseautoimmunitychronic plaque psoriasisIL-17 inhibitorIL-17AIL-17FIL-17RAnanobodynanotechnologyplaque psoriasisplaque-type psoriasispsoriasisrheumatologySecukinumabSonelokimab
Previous Post

#VisualAbstract: Pembrolizumab improves long-term survival in patients with stage III melanoma

Next Post

#VisualAbstract: ChAdOx1 nCov-19 AstraZeneca COVID-19 vaccine not effective against B.1.351 variant

RelatedReports

Hidradenitis suppurativa associated with increased risk of subclinical atherosclerosis
Chronic Disease

Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa

March 16, 2023
Blindness and visual impairment decreasing worldwide
Chronic Disease

Risk of hydroxychloroquine retinopathy increases with longer use and higher dosage

February 1, 2023
Long-term use of apremilast for psoriasis associated with an acceptable safety profile
Chronic Disease

Bimekizumab is effective for active psoriatic arthritis in biologic-naĂŻve adults

January 24, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 5

February 9, 2023
Next Post
#VisualAbstract: ChAdOx1 nCov-19 AstraZeneca COVID-19 vaccine not effective against B.1.351 variant

#VisualAbstract: ChAdOx1 nCov-19 AstraZeneca COVID-19 vaccine not effective against B.1.351 variant

Addressing non-obesity related barriers may improve bariatric surgery effectiveness

Coronary microvascular dysfunction demonstrating improvement after surgery for inflammatory bowel disease

#VisualAbstract: Pembrolizumab improves long-term survival in patients with stage III melanoma

#VisualAbstract: Avelumab does not improve outcomes in patients receiving chemoradiotherapy for squamous cell carcinomas of the head and neck

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Active surveillance strategies to improve rates of inferior vena cava filter retrieval
  • Intranasal vaccine against Bordetella pertussis invokes seronegative IgA response
  • Hydrochlorothiazide does not impact risk of kidney-stone recurrence
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options